Cisplatin in Liver Cancer Therapy

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is the most common primary liver cancer, frequently diagnosed at an advanced, unresectable stage.
• Current treatments like transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) are limited to intrahepatic lesions.
• Systemic therapies have shown limited efficacy, highlighting the need for effective treatment strategies for advanced HCC.

Purpose of the Study:

• To review the mechanisms of action and resistance of cisplatin in treating hepatobiliary cancers.
• To focus on the role of cisplatin in the management of hepatocellular carcinoma (HCC).
• To summarize the application of cisplatin in major hepatobiliary cancers.

Main Methods:

• Literature review summarizing the action and resistance mechanisms of cisplatin.
• Analysis of cisplatin's use in treating major hepatobiliary cancers, with an emphasis on HCC.
• Discussion of treatment strategies for cisplatin-refractory HCC.

Main Results:

• Cisplatin is utilized for local treatment of unresectable advanced HCC via transhepatic arterial administration.
• Drug resistance to cisplatin is a significant challenge, necessitating alternative therapeutic approaches.
• Understanding resistance mechanisms is key to developing subsequent systemic therapies with different mechanisms of action.

Conclusions:

• Cisplatin is an important agent in managing hepatobiliary cancers, including HCC.
• Addressing cisplatin resistance is critical for improving treatment outcomes in advanced HCC.
• Further research into novel therapeutic strategies is warranted for cisplatin-refractory cases.